Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis

Scartozzi, Mario;
2023-01-01

Abstract

The current standard of care for resected early-stage triple negative breast cancer (TNBC) patients who did not receive systemic preoperative therapy is adjuvant anthracycline- and taxane-based chemotherapy (CT). A network meta-analysis (NMA) of randomized controlled trials (phase III) enrolling patients with resected stage I-III TNBC comparing adjuvant regimens was performed. Overall survival (OS) and disease-free survival (DFS) data were extracted. A total of 27 phase III clinical trials were selected including 15,242 TNBC patients. This NMA showed an OS benefit from the incorporation of capecitabine into classic anthracycline/taxane-based combinations compared to anthracyclines with or without taxanes alone.
2023
2022
Inglese
67
8
13
6
Esperti anonimi
scientifica
Adjuvant therapy; Capecitabine; Network meta-analysis; Prognosis; Resected triple negative breast cancer
Goal 3: Good health and well-being
Petrelli, Fausto; Bertaglia, Valentina; Parati, Maria Chiara; Borgonovo, Karen; De Silva, Pushpamali; Luciani, Andrea; Novello, Silvia; Scartozzi, Mar ...espandi
1.1 Articolo in rivista
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
10
open
Files in This Item:
File Size Format  
main-3.pdf

open access

Type: versione editoriale
Size 1.7 MB
Format Adobe PDF
1.7 MB Adobe PDF View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie